EU SMA-TB Financing: PROTrEIN is funded by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 956148
Duration: January 2021 – December 2024
Web: http://protrein.eu/



Consortium description

PROTrEIN is a European Innovative Training Network composed of 11 beneficiaries, and 6 partner organizations, from the academic and non-academic sectors (including two SMEs and two large companies).

  • CRG: Fundacio Centre de Regulacio Genomica, Barcelona, under the coordination of Eduard Sabidó
  • SDU: University of Southern Denmark, Odense, with Veit Schwämmle
  • MPI: Max Planck Institute of Biochemistry, Martinsried, with Jürgen Cox
  • VIB: Vlaams Instituut voor Biotechnologie, Flanders with Sven Degroeve
  • CNRS: Institute of Pharmacology & Structural Biology, Toulouse, with David Bouyssié
  • TUM: Technical University of Munich, Munich, with Mathias Wilhelm
  • ANAXOMICS: ANAXOMICS BIOTECH SL, Barcelona, with Judith Farrés
  • EKUT: Eberhard Karls Universitaet Tübingen, Tübingen, with Timo Sachsenberg
  • FH OOE: University of Applied Sciences Upper Austria, Hagenberg, with Viktoria Dorfer
  • THERMO: Thermo Fisher Scientific GmbH, Bremen with Bernard Delanghe
  • TAU: Tampere University, Tampere, with Juho Hamari

Project Description

Mass spectrometry-based proteomics is one of the most powerful technologies for studying the cellular proteome, protein interactions, and post-translational modifications. Although several proteomics workflows are well-established methods, the field is fast evolving with new acquisition approaches and generating of high-content data structures. This evolution has expanded the number of applications, and mass spectrometry-based proteomics has become one of the principal platforms in the multi-omics universe. However, many of these developments require the assistance of machine learning approaches to predict peptide properties and to optimize the acquisition of proteomics datasets. Similarly, these new applications often require the development of new processing algorithms to query and interpret raw mass spectrometry data, and therefore reveal hidden proteoforms, interactions, and protein modifications.

Finally, the implementation of new experimental possibilities also requires the development of interactive and highly-visual tools for the integration and representation of proteomics data with other omics datasets. Addressing these different needs is crucial to use proteomics at its full potential and thus deliver key contributions in our understanding of biological processes to support the health sector with valuable information.

PROTrEIN will exploit the integrated analysis of several state-of-the-art technologies to achieve these ambitious goals. We are excited to take part in this network.